Literature DB >> 26740680

Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases.

Linda Kahr Andersen1, Kirsten Lykke Knak2, Nanna Witting2, John Vissing2.   

Abstract

OBJECTIVE: This methodologic study investigates if the 2-minute walk test (2MWT) can be a valid alternative to the 6-minute walk test (6MWT) to describe walking capability in patients with neuromuscular diseases.
METHODS: Patients (n = 115) with different neuromuscular diseases were invited to participate on 2 test days, each consisting of 1 2MWT and 1 6MWT separated by a minimum 30-minute period of rest. The order of the walk tests was randomly assigned via sealed envelopes. A group of 38 healthy controls completed 1 6MWT.
RESULTS: The mean walking distance for the 2MWT was 142.8 meters and for the 6MWT 405.3 meters. The distance walked in the 2MWT was highly correlated to the distance walked in the 6MWT (r = 0.99, p < 0.001). There was a significant decrease in walking speed from the first to last minute in the 6MWT, both among patients and healthy controls, which was not evident in the 2MWT. Results were consistent across diagnoses and levels of disease severity.
CONCLUSION: The 2MWT is a potential alternative to the 6MWT to describe walking capability among patients with neuromuscular diseases during clinical trials.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Year:  2016        PMID: 26740680     DOI: 10.1212/WNL.0000000000002332

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Authors:  V J Block; A Lizée; E Crabtree-Hartman; C J Bevan; J S Graves; R Bove; A J Green; B Nourbakhsh; M Tremblay; P-A Gourraud; M Y Ng; M J Pletcher; J E Olgin; G M Marcus; D D Allen; B A C Cree; J M Gelfand
Journal:  J Neurol       Date:  2016-11-28       Impact factor: 4.849

2.  The effect of shoe cushioning on gait and balance in females with multiple sclerosis.

Authors:  Andrew S Monaghan; Patrick G Monaghan; Sutton B Richmond; Jamie A Roper; Brett W Fling
Journal:  Exp Brain Res       Date:  2021-07-01       Impact factor: 1.972

3.  The Combined Efficacy of a Two-Year Period of Cybernic Treatment With a Wearable Cyborg Hybrid-Assistive Limb and Leuprorelin Therapy in a Patient With Spinal and Bulbar Muscular Atrophy: A Case Report.

Authors:  Hideaki Nakatsuji; Tetsuhiko Ikeda; Atsushi Hashizume; Masahisa Katsuno; Gen Sobue; Takashi Nakajima
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

4.  Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Authors:  J W Witherspoon; R Vasavada; R H Logaraj; M Waite; J Collins; C Shieh; K Meilleur; C Bönnemann; M Jain
Journal:  Eur J Paediatr Neurol       Date:  2018-10-23       Impact factor: 3.140

5.  A study on nonlinear estimation of submaximal effort tolerance based on the generalized MET concept and the 6MWT in pulmonary rehabilitation.

Authors:  Jan Szczegielniak; Krzysztof J Latawiec; Jacek Łuniewski; Rafał Stanisławski; Katarzyna Bogacz; Marcin Krajczy; Marek Rydel
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

6.  Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial.

Authors:  Simone Schmidt; Vanya Gocheva; Thomas Zumbrunn; Daniela Rubino-Nacht; Ulrike Bonati; Dirk Fischer; Patricia Hafner
Journal:  Trials       Date:  2017-03-09       Impact factor: 2.279

Review 7.  Lower extremity outcome measures: considerations for clinical trials in spinal cord injury.

Authors:  Marc Bolliger; Andrew R Blight; Edelle C Field-Fote; Kristin Musselman; Serge Rossignol; Dorothy Barthélemy; Laurent Bouyer; Milos R Popovic; Jan M Schwab; Michael L Boninger; Keith E Tansey; Giorgio Scivoletto; Naomi Kleitman; Linda A T Jones; Dany H Gagnon; Sylvie Nadeau; Dirk Haupt; Lea Awai; Chris S Easthope; Björn Zörner; Ruediger Rupp; Dan Lammertse; Armin Curt; John Steeves
Journal:  Spinal Cord       Date:  2018-04-27       Impact factor: 2.772

8.  6-minute walk test as a measure of disease progression and fatigability in a cohort of individuals with RYR1-related myopathies.

Authors:  Jessica W Witherspoon; Ruhi P Vasavada; Melissa R Waite; Monique Shelton; Irene C Chrismer; Paul G Wakim; Minal S Jain; Carsten G Bönnemann; Katherine G Meilleur
Journal:  Orphanet J Rare Dis       Date:  2018-07-03       Impact factor: 4.123

9.  Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001).

Authors:  Takashi Nakajima; Yoshiyuki Sankai; Shinjiro Takata; Yoko Kobayashi; Yoshihito Ando; Masanori Nakagawa; Toshio Saito; Kayoko Saito; Chiho Ishida; Akira Tamaoka; Takako Saotome; Tetsuo Ikai; Hisako Endo; Kazuhiro Ishii; Mitsuya Morita; Takashi Maeno; Kiyonobu Komai; Tetsuhiko Ikeda; Yuka Ishikawa; Shinichiro Maeshima; Masashi Aoki; Michiya Ito; Tatsuya Mima; Toshihiko Miura; Jun Matsuda; Yumiko Kawaguchi; Tomohiro Hayashi; Masahiro Shingu; Hiroaki Kawamoto
Journal:  Orphanet J Rare Dis       Date:  2021-07-07       Impact factor: 4.123

10.  Reference values of gait using APDM movement monitoring inertial sensor system.

Authors:  Xin Fang; Chuandao Liu; Zhongli Jiang
Journal:  R Soc Open Sci       Date:  2018-01-10       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.